Literature DB >> 8043983

Treatment of a patient with malignant mesothelioma with interferon-alpha 2 based on in vitro sensitivity tests.

V Sexl1, L Wagner, M Wiesholzer, E Presterl, W Base.   

Abstract

The case of a 70-year-old patient with an epithelial mesothelioma is presented. The patient suffered from dyspnea due to a right-sided recurrent hemorrhagic effusion. Cytological analysis of the effusion revealed marked lymphocytosis and tumor cells, some of them multinucleated with prominent nucleoli. Open lung biopsy revealed nodular thickening of the diaphragmatic, visceral, and parietal pleura; histological examination of biopsies detected intravascular growth of tumor cells. Immunocytochemical characterization of cultured tumor cells and the biopsy specimens showed positive staining to vimentin and cytokeratin, but negative reaction with antibodies against epithelial membrane associated antigen, leukocyte common antigen, van Willebrand factor, and neurofilament. Hence, the tumor was classified as malignant mesothelioma. In vitro, interferon-alpha 2 produced a dose-dependent inhibition of proliferation in the cultured mesothelioma cells. Two weeks after initiation of interferon-alpha 2 treatment the patient improved and the pleural effusion vanished.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8043983     DOI: 10.1007/bf00180050

Source DB:  PubMed          Journal:  Clin Investig        ISSN: 0941-0198


  12 in total

1.  Augmentation of activity of cis-diamminedichloroplatinum(II) and mitomycin C by interferon in human malignant mesothelioma xenografts in nude mice.

Authors:  N T Sklarin; A P Chahinian; E J Feuer; L A Lahman; L Szrajer; J F Holland
Journal:  Cancer Res       Date:  1988-01-01       Impact factor: 12.701

2.  Induction of perforin and serine esterases in a murine cytotoxic T lymphocyte clone.

Authors:  C C Liu; S V Joag; B S Kwon; J D Young
Journal:  J Immunol       Date:  1990-02-15       Impact factor: 5.422

3.  Activity of intrapleural recombinant gamma-interferon in malignant mesothelioma.

Authors:  C Boutin; J R Viallat; N Van Zandwijk; J T Douillard; J C Paillard; J C Guerin; P Mignot; J Migueres; F Varlet; A Jehan
Journal:  Cancer       Date:  1991-04-15       Impact factor: 6.860

4.  Diffuse malignant mesothelioma presenting as bilateral malignant lymphangitis.

Authors:  K Solomons; R Polakow; P Marchand
Journal:  Thorax       Date:  1985-09       Impact factor: 9.139

Review 5.  Malignant mesothelioma of the pleura.

Authors:  R J Pisani; T V Colby; D E Williams
Journal:  Mayo Clin Proc       Date:  1988-12       Impact factor: 7.616

6.  Phase II evaluation of recombinant interferon-beta (IFN-beta ser) in patients with diffuse mesothelioma: a Southwest Oncology Group study.

Authors:  D D Von Hoff; B Metch; J G Lucas; S P Balcerzak; S M Grunberg; S E Rivkin
Journal:  J Interferon Res       Date:  1990-10

7.  Role of interferon in augmentation of natural and antibody-dependent cell-mediated cytotoxicity.

Authors:  R B Herberman; J Y Djeu; J R Ortaldo; H T Holden; W H West; G D Bonnard
Journal:  Cancer Treat Rep       Date:  1978-11

8.  Diffuse malignant mesothelioma of pleura. Diagnosis and survival in 92 cases.

Authors:  V I Adams; K K Unni; J R Muhm; J R Jett; D M Ilstrup; P E Bernatz
Journal:  Cancer       Date:  1986-10-01       Impact factor: 6.860

9.  Malignant mesothelioma: the antiproliferative effect of cytokine combinations on three human mesothelioma cell lines.

Authors:  A M Hand; K Husgafvel-Pursiainen; L Tammilehto; K Mattson; K Linnainmaa
Journal:  Cancer Lett       Date:  1991-07-04       Impact factor: 8.679

10.  A novel serine esterase expressed by cytotoxic T lymphocytes.

Authors:  M S Pasternack; H N Eisen
Journal:  Nature       Date:  1985 Apr 25-May 1       Impact factor: 49.962

View more
  1 in total

1.  Integrated genomics point to immune vulnerabilities in pleural mesothelioma.

Authors:  Anca Nastase; Amit Mandal; Shir Kiong Lu; Hima Anbunathan; Deborah Morris-Rosendahl; Yu Zhi Zhang; Xiao-Ming Sun; Spyridon Gennatas; Robert C Rintoul; Matthew Edwards; Alex Bowman; Tatyana Chernova; Tim Benepal; Eric Lim; Anthony Newman Taylor; Andrew G Nicholson; Sanjay Popat; Anne E Willis; Marion MacFarlane; Mark Lathrop; Anne M Bowcock; Miriam F Moffatt; William O C M Cookson
Journal:  Sci Rep       Date:  2021-09-27       Impact factor: 4.379

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.